



## PRANA BIOTECHNOLOGY EGM AND CONFERENCE CALL FACILITY

**MELBOURNE, March 27<sup>th</sup> 2019:** Prana Biotechnology (ASX: PBT, NASDAQ PRAN) today advises that a conference call facility will be available at the Extraordinary General Meeting (EGM) scheduled for Friday, April 5, 2019, at 11:00 AM AEDT.

Shareholders will vote on the transaction with Boston based Life Biosciences LLC and the appointment of Dr David Sinclair and Mr Tristan Edwards on the Board of Directors. In addition, shareholders will also vote on a change of name to Alterity Therapeutics Limited and ratification of prior issue of shares.

Shareholders can pre-register at the link below:

<https://services.choruscall.com.au/diamondpass/prana-167745-invite.html>

If you are unable to use the "Register Now" button above, then at the time of the conference you can call one of the numbers below and provide the **conference ID 167745** to an operator.

<b>Australia Toll Free:</b>	<b>1 800 558 698</b>
Alternate Australia Toll Free:	1 800 809 971
Australia Local:	02 9007 3187
Singapore:	800 101 2785
Hong Kong:	800 966 806
United States:	(855) 881 1339
US Local (New York):	(914) 202 3258
US Local (Los Angeles):	(909) 235 4020
US Local (Chicago):	(815) 373 2080

### Contact:

#### Investor Relations

Rebecca Wilson

E: [rwilson@bucanwe.com.au](mailto:rwilson@bucanwe.com.au)

Tp: +61 3 9866 4722

### About Prana Biotechnology Limited

Prana's lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of  $\alpha$ -synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical parkinsonism such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).

For further information, please visit the Company's web site at [www.pranabio.com](http://www.pranabio.com).

## Forward Looking Statements

*This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factors including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.*